Want to see CAMP full AI Analyst Report?

CAMP4 Therapeutics Corporation (CAMP) Price & Analysis

132 Followers

CAMP Stock Chart & Stats

$3.16

$0.15(4.98%)

At close: Jul 24 4:00 PM EDT

$3.16

$0.15(4.98%)

Day’s Range― - ―

52-Week Range$1.36 - $7.75

Previous Close$4.45

Volume169.64K

Average Volume (3M)299.74K

Market Cap

$219.13M

Enterprise Value-$9.15M

Total Cash (Recent Filing)$99.21M

Total Debt (Recent Filing)$2.12M

Price to Earnings (P/E)―

Beta1.94

Next Earnings

Aug 13, 2026

EPS Estimate

-0.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.27

Shares Outstanding62,753,200

10 Day Avg. Volume187,795

30 Day Avg. Volume299,741

Financial Highlights & Ratios

PEG Ratio6.15

Price to Book (P/B)3.90

Price to Sales (P/S)53.24

P/FCF Ratio-6.24

Enterprise Value/Market Cap-0.04

Enterprise Value/Revenue-2.33

Enterprise Value/Gross Profit-3.05

Enterprise Value/Ebitda0.18

Forecast

1Y Price Target

$8.88

Price Target Upside180.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.81

Revenue Forecast (FY)$6.23M

Bulls Say, Bears Say

Bulls Say

Regulatory Clearance To Start Phase 1/2Regulatory approval to open first-in-human sites is a durable clinical milestone: it enables patient enrollment, validates trial design and safety plans, and materially de-risks early development timing. This structural step improves the program's path toward proof-of-concept and future partnering options.

Substantial Private Financing CompletedA $100M private placement provides multi-month runway to advance CMP-002 and early programs without immediate public dilution. Durable impact: strengthens liquidity to fund clinical operations and preclinical work, enabling milestone execution that can increase optionality for partnering or future financings.

Preclinical Efficacy For Lead ASO CandidateRobust in vivo efficacy in disease-relevant models supports translational probability. For an RNA-regulatory platform, reproducible preclinical benefit across endpoints underpins scientific credibility, increases the likelihood of meaningful clinical signals, and strengthens the company’s competitive position in rare CNS genetics.

Bears Say

Sustained High Cash BurnPersistent negative operating and free cash flow means ongoing reliance on external capital to fund development. Over the medium term this elevates dilution risk and constrains strategic flexibility; absent material revenue or cost reductions, funding needs will recur as programs progress.

Very Large Recurring Net LossesSubstantial, recurring losses indicate the business remains pre-commercial and unable to self-finance R&D. Continued negative profitability erodes equity and limits reinvestment capacity; long-term viability is contingent on successful clinical advancement or new non-dilutive funding sources.

Small, Declining Revenue BaseMinimal and shrinking revenues mean the company lacks diversified operating cash sources. Reliance on milestone-driven financings increases funding volatility and heightens execution risk; without commercial products, revenue growth is uncertain and margins remain dependent on external capital.

CAMP4 Therapeutics Corporation News

Camp4 Therapeutics receives Australia TGA clearance for CMP-002 trial

CAMP4 Therapeutics (CAMP) announced that it has received clearance from Australia’s Therapeutic Goods Administration, or TGA, and local...

17d ago

CAMP

CAMP Upcoming Earnings Report: What to Expect?

CAMP4 Therapeutics Corporation (CAMP) is scheduled to report 2nd quarter earnings on 08/13/2026. Regarding Q2 estimates, Wall Street...

2d ago

CAMP

CAMP4 Therapeutics Secures $50 Million Private Financing

CAMP4 Therapeutics Corporation ( ($CAMP) ) has issued an update. On August 3, 2026, CAMP4 Therapeutics completed the...

9d ago

CAMP

CAMP4 gains Australian clearance, enabling CMP-002 trial and financing

CAMP4 Therapeutics Corporation ( ($CAMP) ) has provided an update. On July 27, 2026, CAMP4 Therapeutics announced it...

17d ago

CAMP

X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board

X4 Pharmaceuticals (XFOR) announced the appointment of Kelly Gold to the company’s board of directors effective July 1,...

1M ago

CAMP

XFOR

Camp4 Therapeutics upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Camp4 Therapeutics (CAMP) to Overweight from Neutral with a price target of $9, up from $5....

2M ago

CAMP

CAMP4 Shareholders Approve Equity Plan Changes and Inducement Plan

CAMP4 Therapeutics Corporation ( ($CAMP) ) just unveiled an announcement. On June 10, 2026, CAMP4 Therapeutics stockholders approved...

2M ago

CAMP

Camp4 Therapeutics initiated with a Buy at Chardan

Chardan analyst Keay Nakae initiated coverage of Camp4 Therapeutics (CAMP) with a Buy rating and $6.50 price target...

2M ago

CAMP

CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy

The latest announcement is out from CAMP4 Therapeutics Corporation ( ($CAMP) ). On May 14, 2026, CAMP4 Therapeutics...

3M ago

CAMP

Buy Rating Reaffirmed on CAMP4 as CMP-002 Advances Toward 2026 SYNGAP1 Trial and Strong Cash Runway Extends Into 2028

Analyst Yun Zhong of Wedbush maintained a Buy rating on CAMP4 Therapeutics Corporation, with a price target of...

3M ago

CAMP

Camp4 Therapeutics reports Q1 EPS (32c), consensus (21c)

Reports Q1 revenue $1.29M, consensus $1.12M. “We have made significant progress year-to-date against our goal of bringing a...

3M ago

CAMP

Camp4 Therapeutics initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw analyst Seema Sheoran initiated coverage of Camp4 Therapeutics (CAMP) with a Buy rating and $7...

4M ago

CAMP

Camp4 Therapeutics price target raised to $9 from $8 at Leerink

Leerink analyst Mani Foroohar raised the firm’s price target on Camp4 Therapeutics (CAMP) to $9 from $8 and...

4M ago

CAMP

CAMP4 Therapeutics Adds Veteran CFO MacLean to Board

The latest update is out from CAMP4 Therapeutics Corporation ( ($CAMP) ). On March 18, 2026, CAMP4 Therapeutics’...

5M ago

CAMP

CAMP FAQ

What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?

CAMP4 Therapeutics Corporation lowest stock price was $1.36 and its highest was $7.75 in the past 12 months.

What is CAMP4 Therapeutics Corporation’s market cap?

CAMP4 Therapeutics Corporation’s market cap is $219.13M.

When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?

CAMP4 Therapeutics Corporation’s upcoming earnings report date is Aug 13, 2026 which is today.

How were CAMP4 Therapeutics Corporation’s earnings last quarter?

CAMP4 Therapeutics Corporation released its earnings results on May 07, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.21 by -$0.11.

Is CAMP4 Therapeutics Corporation overvalued?

According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CAMP4 Therapeutics Corporation pay dividends?

CAMP4 Therapeutics Corporation does not currently pay dividends.

What is CAMP4 Therapeutics Corporation’s EPS estimate?

CAMP4 Therapeutics Corporation’s EPS estimate is -0.21.

How many shares outstanding does CAMP4 Therapeutics Corporation have?

CAMP4 Therapeutics Corporation has 62,753,200 shares outstanding.

What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?

CAMP4 Therapeutics Corporation reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.21. Following the earnings report the stock price went up 2.765%.

Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?

Currently, no hedge funds are holding shares in CAMP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CAMP4 Therapeutics Corporation Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

68.00%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

CAMP4 Therapeutics Corporation (CAMP) Earnings & Revenues

Historic Earnings Reports

CAMP Stock 12 Month Forecast

Average Price Target

$8.88

▲(180.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.45,4.107692307692308,4.765384615384615,5.423076923076923,6.080769230769231,6.738461538461539,7.396153846153847,8.053846153846155,8.711538461538463,9.369230769230771,10.02692307692308,10.684615384615386,11.342307692307694,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.45,3.8673076923076923,4.2846153846153845,4.701923076923077,5.11923076923077,5.536538461538461,5.953846153846154,6.371153846153846,6.788461538461538,7.2057692307692305,7.623076923076923,8.040384615384614,8.457692307692309,{"y":8.875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.45,3.684615384615385,3.9192307692307695,4.153846153846154,4.388461538461539,4.6230769230769235,4.857692307692307,5.092307692307692,5.326923076923077,5.561538461538461,5.796153846153846,6.030769230769231,6.265384615384615,{"y":6.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.415,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.34,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >